Research presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients with myelodysplastic syndrome (MDS) have worse overall survival outcomes than African American patients, contrary to previous findings in other cancer types.
Disparities in cancer care and outcomes between African American patients and White patients have been demonstrated in past studies, with African American patients often experiencing worse outcomes. Regarding myelodysplastic syndrome (MDS), however, an abstract presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients to have worse overall survival (OS) outcomes than African Americans patients.
MDS encompasses a group of clonal myeloid neoplasms first defined as malignant in 2001. The causes of MDS are often unknown, but in some cases, it can occur secondary to mutations caused by cancer therapies or other external factors. MDS can also evolve into acute myeloid leukemia (AML). Considering that past studies have found African Americans to have worse outcomes than White patients in several solid tumor and hematological cancers, including AML, the current study aimed to characterize baseline traits and outcomes in patients with MDS.
Researchers analyzed data from the Survival, Epidemiology, and End Results (SEER) cancer registry to analyze outcomes in 37,564 patients aged 20 years or older with confirmed MDS between 2000 and 2013. Patients were stratified into low-, intermediate-, and high-risk disease groups.
A total of 34,543 White patients (91.9%) and 3021 Black patients (8.1%) were included in the study, which compared patients’ baseline characteristics, mortality rates per cause of death, and OS. The median ages at diagnosis were 76 and 71 years, respectively. There was a higher proportion of men in the White study population vs in the African American population (58% vs 49%). Further, more African American patients were considered low risk (22.8% vs 21.5%) and fewer patients were considered high risk (14.5% vs 16.3%).
The median OS for African American patients was 33 months vs 26 months in White patients, and they were shown to have a 21% reduced risk of MDS-related mortality (HR, 0.79; 95% CI, 0.76-0.83; P < .001). The most common causes of death in both patient cohorts was MDS/leukemia, cardiovascular disease, and other cancers. The relationship between race and OS remained statistically significant when baseline covariates were adjusted in a multivariate Cox proportional hazards regression model.
The study was limited by its retrospective nature; its reliance on data only available in SEER, and the lack of data on subtypes of MDS, which is a heterogenous group of clonal myeloid neoplasms. Even so, the finding that African American patients had better OS than White patients with MDS warrants further research, the authors conclude.
These data differ from prior research on the disparities between African American and White patients with hematological malignancies.
Reference
Lesegretain A, Laadem A, Fell G, Fathi AT. Comparison of demographics, disease characteristics, and outcomes between African American patients and White patients with myelodysplastic syndrome: a population-based study. Abstract presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022; Chicago, IL. Accessed June 22, 2022. Abstract 7051. https://meetings.asco.org/abstracts-presentations/208243
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More